Darunavir Krka d.d. is an antiviral medicine used with other HIV medicines to treat patients with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is given with low-dose ritonavir or, in adults, with cobicistat. Darunavir Krka d.d. may be given to adults or children from 3 years of age and weighing at least 15 kg.
Darunavir Krka d.d. contains the active substance darunavir.
Darunavir Krka d.d. is a ‘generic medicine’. This means that Darunavir Krka d.d. contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the European Union (EU) called Prezista.
The active substance in Darunavir Krka d.d., darunavir, is a protease inhibitor. It blocks protease, an enzyme involved in the reproduction of HIV. When the enzyme is blocked, the virus does not reproduce normally, slowing down its multiplication in the body. Darunavir Krka d.d. is always given with ritonavir. Ritonavir reduces the breakdown of darunavir, increasing the levels of darunavir in the blood. This allows effective treatment while avoiding a higher dose of darunavir.
Darunavir Krka d.d., taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level. Darunavir Krka d.d. does not cure HIV infection or AIDS, but HIV treatment may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at firstname.lastname@example.org
We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.